Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Batra And Galinat Appointed To Merck Board

This article was originally published in Scrip

Executive Summary

E. Merck KG, the family holding company of Merck KGaA, has appointed Udit Batra, head of the life science business sector, and Walter Galinat, head of the performance materials business sector, to Merck KgaA's executive board – effective April, 30. 2016. Current board member Bernd Reckmann, will retire from his position – effective April. 30, 2016. Galinat joined Merck as an apprentice in 1976 and after earning his degree he built up the local Merck subsidiary in Taiwan. Later on in his career, he was head of the laboratory products division, head of the former Liquid Crystals division and was appointed CEO and president of today's performance materials business sector. Before joining Merck, Batra was at Novartis, where he was head of global public health and market access for vaccine and diagnostics, global head of corporate strategy and country president of the pharmaceutical business in Australia. He joined Merck in 2011, taking over leadership of the consumer health business and was later appointed CEO and president of Merck Millipore.

You may also be interested in...



Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?

How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.

Adherence Issues Add Weight To Digital Trials Push

Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.

Appointments: Five Prime, Depomed, Gilead, Arix Bioscience and Corbus

This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.

Topics

UsernamePublicRestriction

Register

OM005385

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel